Zheng Song, Pan Yue-Long, Tao De-You, Wang Jiao-Li, Huang Ke-Er
Department of Oncology, Hangzhou First People's Hospital of Zhejiang Province, Hangzhou, China.
Scand J Gastroenterol. 2009;44(6):760-3. doi: 10.1080/00365520802647459.
C-kit gene gain of function mutations are important in the pathogenesis of gastrointestinal stromal tumors (GISTs). Imatinib is a selective tyrosine kinase inhibitor of KIT and achieves a partial response or stable disease in most patients with metastatic GIST, but there is increasing evidence of acquired resistance. We report a case of GIST with acquired resistance to imatinib during therapy and secondary c-kit mutation besides the primary mutation.
C-kit基因功能获得性突变在胃肠道间质瘤（GISTs）的发病机制中具有重要作用。伊马替尼是一种KIT选择性酪氨酸激酶抑制剂，在大多数转移性GIST患者中可实现部分缓解或病情稳定，但越来越多的证据表明存在获得性耐药。我们报告了1例GIST患者，在治疗期间对伊马替尼产生获得性耐药，且除原发性突变外还出现了继发性c-kit突变。
